These two biotechs have major drugs that should be hitting the market soon.
News & Analysis: Immunomedics
Fast-approaching catalysts could make these biotech stocks top performers this year.
Optimism is high that the company's lead pipeline candidate can secure an FDA OK.
Several companies raised capital on Wednesday.
IMMU earnings call for the period ending September 30, 2019.
It's highly likely that Immunomedics' billion-dollar drug will finally be approved by the FDA.
Major binary events like late-stage clinical trial results or drug approvals offer high-risk, high-reward opportunities for those who can stomach the uncertainty.
Unfortunately, there were more of the latter.
The market isn't pleased with its latest clinical update.
Doctors, researchers, and pharmaceutical experts will converge upon Barcelona to share the latest results in cancer research. Here is a run-down on three to watch.